Blockchain Registration Transaction Record

Monod Bio and SignalChem Biotech Forge Licensing Deal for AI-Designed Proteins

Monod Bio and SignalChem Biotech sign licensing agreement to integrate AI-designed LuxSit luciferase and NovoBodies into custom assay services, accelerating drug discovery.

This licensing agreement is important because it brings Monod Bio's cutting-edge AI-designed proteins—LuxSit luciferase and NovoBodies—into the hands of researchers through SignalChem Biotech's established CRO services. By integrating these advanced tools into custom assay development, the partnership promises to accelerate drug discovery and life science research. For scientists, this means faster access to high-quality discovery candidates, more efficient workflows, and the ability to tackle complex biological questions with innovative tools. For the broader industry, it signals a growing trend of AI-enabled technologies being adopted by major life science companies, potentially transforming how research is conducted and leading to breakthroughs in diagnostics and therapeutics.